HHS & Healthcare Contracts Intelligence — April 08, 2026

Shionogi Inc awarded $119,160,691 cost-plus-fixed-fee contract by HHS BARDA for 10-year late-stage development and procurement of antibiotics targeting drug-resistant and biothreat pathogens, with base + options up to $481M under full and open competition.

Vedanta Biosciences has outlayed $70,681,089 of $79,146,088 HHS BARDA cost-sharing contract awarded in 2020 for biotechnology R&D against antibiotic-resistant infections, with options to $114M and potential extension to 2031.

DLA Troop Support awarded $102,615,000 federal grant from HHS with unknown revenue details or performance structure.

Shionogi Inc's $119M HHS BARDA contract has $0 outlays to date despite April 2026 award, signaling potential delays in funding flow for 10-year performance period.

Vedanta Biosciences' $79M HHS BARDA contract is cost-sharing with medium pricing risk and unexercised $35M options, plus uncertain extension beyond 2027-01-31.

Shionogi Inc's HHS BARDA contract offers up to $481M base + options over 10 years for biothreat antibiotics R&D.

Vedanta Biosciences' HHS BARDA contract has $35M unexercised options and potential extension to 2031 for antibiotic resistance countermeasures.

HHS BARDA awarded $198M+ obligations to Shionogi Inc ($119M, potential $481M) and Vedanta Biosciences ($79M, $70M outlayed, potential $114M) for NAICS 541714 biotech R&D targeting drug-resistant infections and biothreat pathogens under full and open competition.

{"entity"=>"Shionogi Inc", "reason"=>"$119M HHS BARDA obligation with $0 outlays and potential $481M options over 10 years", "trigger"=>"outlay progress from $0, option exercises, FDA milestones"}

{"entity"=>"Vedanta Biosciences", "reason"=>"$79M HHS BARDA obligation with $70M outlayed, $35M options, and 2027 end vs 2031 potential", "trigger"=>"remaining drawdown, option exercises, extension to 2031-12-31"}

{"entity"=>"HHS BARDA biotech R&D sector", "reason"=>"Two high-materiality awards totaling $198M signal priorities in biothreat antibiotics", "trigger"=>"outlay and option progress on Shionogi and Vedanta contracts"}